So far, seven children from around the world who are on the trial have survived longer than two years, and one child in Sydney has survived five years, Dun said.He said from the trial’s preliminary data, there has been a nine to eight month survival extension for patients who have also completed radiotherapy.
The team working on the PNOC-022 trial hope by mid-2024 they will be able to report on the trial’s results and the drug’s side effects, which Dun said could include nausea, rashes and mouth ulcers.
If the results demonstrate success, they will apply to the United States Food and Drug Administration to approve the drug, and then the Therapeutic Goods Administration in Australia.
KZA Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held
